- Home
- OI vs PGEN Comparison
OI vs PGEN Comparison
Compare OI & PGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | OI | PGEN |
|---|---|---|
| Founded | 1903 | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Containers/Packaging | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.6B | 1.6B |
| IPO Year | 1994 | 2013 |
Fundamental Metrics
Financial Performance| Metric | OI | PGEN |
|---|---|---|
| Price | $9.25 | $5.54 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 7 | 5 |
| Target Price | ★ $15.29 | $8.33 |
| AVG Volume (30 Days) | 2.7M | ★ 5.8M |
| Earning Date | 04-28-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $6,426,000,000.00 | $230,981,000.00 |
| Revenue This Year | $2.77 | $1,115.92 |
| Revenue Next Year | $1.88 | $81.04 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $7.75 | $1.47 |
| 52 Week High | $16.91 | $6.04 |
Technical Indicators
Market Signals| Indicator | OI | PGEN |
|---|---|---|
| Relative Strength Index (RSI) | 48.52 | 60.28 |
| Support Level | $8.95 | $3.96 |
| Resistance Level | $9.62 | $6.04 |
| Average True Range (ATR) | 0.36 | 0.35 |
| MACD | 0.02 | -0.01 |
| Stochastic Oscillator | 24.15 | 62.76 |
Price Performance
Historical ComparisonAbout OI O-I Glass Inc.
O-I Glass is the manufacturer of glass containers. The Company has two reportable segments and two operating segments based on its geographic locations: Americas and Europe. Beer is the primary end market for O-I's glass bottles, which are also used for wine, soda, spirits, condiments, and food.
About PGEN Precigen Inc.
Precigen Inc is a commercial-stage biopharmaceutical company focused on developing precision medicines to improve the lives of patients, targeting immuno-oncology, autoimmune disorders, and infectious diseases using its proprietary and complementary technology platforms. These platforms support the development of gene programs, delivery through viral, non-viral, and microbe-based approaches, and control of gene expression for safety and efficacy. Its key platforms include AdenoVerse immunotherapy and UltraCAR-T, supported by the UltraPorator device for rapid and cost-effective manufacturing. Its clinical pipeline includes PRGN-2009, PRGN-3005, PRGN-3006, and PRGN-3007. Its reportable segments are Biopharmaceuticals and Exemplar.